Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation

European Journal of Cancer Part B: Oral Oncology

Volumn 32, Issue 3, 1996, Pages 158-162

  Epstein, J B ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Bone marrow transplantation; Oral herpes virus

Indexed keywords

ACICLOVIR; CYCLOSPORIN; FOLINIC ACID; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; FEMALE; GRAFT REJECTION; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MOUTH INFECTION; PRIORITY JOURNAL;

EID: 0029937142     PISSN: 09641955     EISSN: None     Source Type: Journal    
DOI: 10.1016/0964-1955(95)00091-7     Document Type: Article

References (61)

1. Wade JC, Day LM, Crowley JJ, Meyers JD. Recurrent infection with herpes simplex virus after marrow transplantation: role of the specific immune response and acyclovir treatment. J Infect Dis 1984, 149,750-756.
2. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984, 100, 823-828.
3. Lam MT, Pazin GJ, Armstrong JA, Ho M. Herpes simplex infection in acute myelogenous leukemia and other hématologie malignancies: prospective study. Cancer 1981, 48, 2168-2171.
4. Rand KH, Kramer B, Johnson AC. Cancer chemotherapy associated symptomatic stomatitis: role of herpes simplex virus (HSV). Cancer 1982, 56, 1262-1265.
5. Strauss SE, Seiden M, TakiffH, Jacoabs D, Bowne D, Smith HA. Oral acyclovir to suppress recurring herpes simplex virus infections in immunodeficient patients. Ann Intern Med 1984, 100,522-524.
6. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988, 30, 17-22.
7. Schubert MM, Peterson DE, Flournoy N, Meyers JD, Truelove EL. Oral and pharyngeal herpes simplex infection after allogeneic bone marrow transplantation : analysis of factors associated with infection. Oral Surg Oral Med Oral Pathol 1990, 70, 286-283.
8. Woo SB, Sonis ST, Sonis AL. The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients. Cancer 1990, 66, 2375-2379.
9. Shibuya T, Moriyama K, Harada M, et al. Herpes simplex virus in oral mucosal ulcers in patients with hematological malignancy. Jap J Clin Oncol 1989, 19, 348-352.
10. Redding SW. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr 1990, 9, 103-105.
11. Schubert MM, Epstein JB, Lloid ME, Cooney E. Oral infections due to cytomeglovirus in immunocompromised patients. J Oral Pathol Med 1993, 22, 268-273.
12. Selby PJ, Powles RL, Easton D, et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989, 59, 434-438.
13. Epstein JB. Antiviral therapeutics in dentistry. Curr Op Dent 1991, 1,436-444.
14. Meyers JD. Chemoprophylaxis of viral infection in immunocompromised patients. Eur J Cancer Clin Oncol 1989, 25, 1369-1374.
15. Balfour HH Jr, Chace B A, Stopleton JT, Simmons RL, Fryd DS. Acyclovir prevents cytomegalovirus disease in renal allograft recipients. A Engl J Med 1989, 320, 384-388.
16. Reed EC, Wolford JL, Kopecky KJ, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone-marrowtransplant patients. Ann Intern Med 1990, 112, 505-510.
17. Ho WG, Winston DJ, Champlin RE. Tolerance and efficacy of ganciclovir in the treatment of cytomegalovirus infections in immunosuppressed patients. Transplant Proc 1989, 21, 3103-3106.
18. Rubie H, Attal M, Campardou AM, et al. Risk factors for cytomeglovirus infection in BMT recipients transfused exclusively with seronegtive blood products. Bone Marrow Transplant 1993, 11, 209-214.
19. Bacigaulupo A, Tedone E, Sanna MA, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Hematologica 1992, 77,507-513.
20. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, doubleblind trial. Ann Intern Med 1993, 118, 179-184.
21. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Mcd 1990, 112,416-422.
22. Wade JC, McLaren C, Meyers JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. j Infect Dis 1983, 148, 1077-1082.
23. Epstein JB, Scully C. Herpes simplex virus in immunocompromised patients: growing evidence of drug resistance. Oral Surg Oral Med Oral Pathol 1991, 72, 47-50.
24. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989, 320, 289-293.
25. Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991, 35,2191-2197.
26. Sullivan V, Coen DM. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral durgs. J Infect Dis 1991, 164, 781-784.
27. Biron KK. Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents. Transplant Proc 1991, 23, 162-167.
28. Knox KK, Drobyski WR, Carrigan DR. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 1991, 337, 1292-1293.
29. Drew WL. Clinical use of ganciclovir for cytomegalovirus infection and the development of drug ressitance. JA IDS 1991, 4 (suppl 1), s42-s46.
30. Field HJ. Development of clinical resistance to acyclovir in herpes-simplex-virus-infected mice receiving oral therapy. Antimicrob Agents Chemother 1982, 21, 744-752.
31. Field HJ, Darby Wildy P. Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. J Gen Virol 1980,49, 115-124.
32. Parris DS, Harrington JE. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother 1982, 22, 71-77.
33. Erlich KS, Mills J, Chads P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989, 320, 293-296.
34. Bean B, Fletcher C, Englund J, Lehrman SN, Ellis MN. Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. Diag Microbiol Infect Dis 1987, 7, 199-204.
35. MacPhail LA, Greenspan D, Shoidt M, Drennan DP, Mills J. Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type II lesion in a patient with AIDS. Oral Surg Oral Med Oral Pathol 1989, 67, 427-432.
36. Crumpacker CS. Significance of resistance of herpes simplex virus to acyclovir. J Am Acad Dermatol 1988, 18, 190-195.
37. Ljungman P, Ellis MN, Hackman RC, Shepp DH, Meyers JD. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 1990, 162, 244-248.
38. Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990, 112, 416-422.
39. Gray JJ, Wreghitt TG, Baglin TP. Susceptibility to acyclovir of herpes simplex virus: emergence of resistance in patients with lymphoid and myeloid neoplasia. J Infection 1989, 19, 31-40.
40. Nevill TJ, Tirgan MH, Deeg HJ, et al. Influence of postmethotrexate follinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992, 9, 349-354.
41. Epstein JB, Sherlock C, Page JL, Spinelli J, Phillips G. Clinical study of herpes simplex virus infection in leukemia. Oral Surg Oral Med Oral Pathol 1990, 70, 38-43.
42. Epstein JB, Page JL, Anderson GH, Spinelli J. The role of an immunoperoxidase technique in the diagnosis of oral herpes simplex virus infection in patients with leukemia. Clin Cytopathol 1987, 3,206-209.
43. Cohen SG, Greenberg MS. Chronic oral herpes simplex virus infection in immunocompromised patients. Oral Surg Oral Med Oral Pathol 1985, 56, 465-471.
44. Greenberg MS, Cohen SG, Boosz B, Friedman H. Oral herpes simplex infections in patients with leukemia. J Am Dent Assoc 1987, 114,483-486.
45. Herzig RH, Worff SN, Lazarus AW, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983, 62, 361-369.
46. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of HLA-matched sibling donors. Transplantation 1974, 18, 295-304.
47. Weisdorf DJ, Snover DC, Hoake R, et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990, 76, 624-629.
48. Hawkes RA. General principles underlying laboratory diagnosis of viral infections. In Lennette EH, Schmidt NJ, eds. Diagnostic Procedures for Viral, Ricketsial and Chlamydial Infections. Washington, DC, American Public Health Association, 1979.
49. Epstein JB, Phillips K, Sherlock CH. Viral serology after bone marrow transplantation. Viral Immunol 1991, 4, 133-137.
50. Epstein JB, Gangbar SJ. Oral mucosal lesions in patients undergoing treatment for leukemia. J Oral Med 1987, 42, 132-137.
51. Wingard JR. Infectious and noninfectious systemic consequences. NCI Monogr 1990, 9, 21-26.
52. Ringden O, Heimdahl A, Linnquist B, et al. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet 1984, 1, 744.
53. Donnelly JP, Muus P, Horrevorts AM, Sauerwein RW, De Pauw BE. Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogeneic bone marrow transplant recipients. ScandJ Infect Dis 1993, 25, 43-50.
54. Redding SW, Montgomery MT. Acyclovir prophylaxis for oral herpes simplex virus infection in patients with bone marrow transplants. Oral Surg Oral Med Oral Pathol 1989, 67, 680-683.
55. Shepp DH, Newton BA, Dandliker PS, Flournoy N, Meyers JD. Oral acyclovir therapy for mucocutaneous herpes simplex virus infection in immunocompromised marrow transplant recipients. Ann Intern Med 1985, 102, 783-785.
56. Prentice HG. Use of acyclovir for prophylaxis of herpes infections in several immunocompromised patients. J Antimicrob Chemother 1983,12,153-159.
57. Sacks SL, Wanklin RL, Reece DE, Hicks KA, Tyler KL, Cohen DM. Progressive esophagitis from acyclovir-resistant herpes simplex: clinical roles for DNA polymerase mutants and viral heterogeneity. Ann Intern Med 1989, 111, 893-899.
58. Chatis PA, Miller CH, Schräger LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N EnglJ Med 1989, 320, 297-300.
59. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994, 343, 749-753.
60. Ljungman P, Aschan J, Azinge JN, et al. Cytomegalovirus viremia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol 1993,83, 118-124.
61. Bostrom L, Ringden O, Forsgren M. Strong donor mononuclear cell reactivity for herpes simplex virus (HSV) antigen in HSV immune donors combined with recipient seropositivity for HSV is associated with acute graft-versus-host disease. Scand J Immunol 1991, 34, 45-52.